Detalhe da pesquisa
1.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665782
2.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495879
3.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37387213
4.
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Jpn J Clin Oncol
; 54(4): 434-443, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231777
5.
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study).
Oncologist
; 28(3): 278-e166, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426809
6.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825192
7.
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Jpn J Clin Oncol
; 53(1): 4-15, 2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36398439
8.
Evaluation of a novel medical device for pegfilgrastim administration.
Cancer Sci
; 113(5): 1763-1770, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293085
9.
A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
Cancer
; 128(8): 1692-1698, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045185
10.
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Acta Med Okayama
; 76(6): 661-671, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36549768
11.
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.
Cancer Immunol Immunother
; 70(2): 337-348, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757055
12.
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Invest New Drugs
; 38(5): 1540-1549, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31950374
13.
[Evaluation of the Benefits of Administering Hand Therapy to Patients with Chemotherapy-Induced Peripheral Neuropathy].
Gan To Kagaku Ryoho
; 47(5): 783-788, 2020 May.
Artigo
em Japonês
| MEDLINE | ID: mdl-32408320
14.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 827-836, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047804
15.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 816-826, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047803
16.
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Int J Cancer
; 145(12): 3414-3424, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087550
17.
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Cancer Sci
; 110(1): 52-60, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30390416
18.
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Oncologist
; 24(3): 327-337, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425180
19.
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
BMC Cancer
; 19(1): 962, 2019 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31619197
20.
Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.
Int J Mol Sci
; 20(16)2019 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31426531